Literature DB >> 8690150

Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production.

G Boden1, X Chen, J L Urbain.   

Abstract

Diurnal variation in insulin sensitivity in patients with NIDDM has long been suspected but has been difficult to document mainly because of the interdependence of changes in glucose and insulin. Stable serum insulin levels during hyperglycemic clamping in patients with NIDDM in the present study provided the opportunity to examine changes in insulin sensitivity unaffected by changes in blood glucose and insulin concentrations. Six patients with NIDDM (four men and two women, BMI 33.9 +/- 2.5) underwent hyperglycemic (11.1 mmol/l, approximately 200 mg/dl) clamping for 72 h. Measured were serum insulin, free fatty acid (FFA), cortisol, and growth hormone concentrations and rates of insulin secretion, insulin clearance, and glucose infusion rate (GIR) needed to maintain hyperglycemia. In addition, five patients (three men and two women, BMI 32.6 +/- 0.6) underwent hyperglycemic clamping for 24 h with hourly determinations of hepatic glucose production (HGP) and glucose disappearance rates (GRd). GIR, reflecting insulin sensitivity, changed rhythmically with a cycle duration of 22.9 +/- 1.4 h and an amplitude of 47.8 +/- 11.2%. GIR was lowest at 8:31 a.m. (+/- 52 min) and highest at 7:04 p.m. (+/- 58 min). Circadian changes in GIR were completely accounted for by changes in HGP, while GRd remained unchanged. Plasma levels of FFAs and cortisol also exhibited circadian fluctuations, and their blood levels correlated negatively with GIR (r = -0.72 and -0.64, respectively). We concluded that insulin sensitivity in patients with NIDDM changed with circadian (approximately 24 h) rhythmicity (decreasing during the night and increasing during the day). These changes were unrelated to blood levels of glucose and insulin, insulin clearance, exercise, food intake, and sleep. They were caused by circadian changes in HGP, which in turn were closely correlated with circadian changes in blood FFA and cortisol levels. We believe that recognition of these circadian changes has implications for the diagnosis and the treatment of patients with NIDDM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690150     DOI: 10.2337/diab.45.8.1044

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  49 in total

Review 1.  Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Authors:  L Monnier; C Colette; S Dejager; D R Owens
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

2.  Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?

Authors:  J Radziuk; S Pye
Journal:  Diabetologia       Date:  2006-05-16       Impact factor: 10.122

3.  Design and in silico evaluation of an intraperitoneal-subcutaneous (IP-SC) artificial pancreas.

Authors:  Justin J Lee; Eyal Dassau; Howard Zisser; Francis J Doyle
Journal:  Comput Chem Eng       Date:  2014-11-05       Impact factor: 3.845

4.  Diurnal rhythms in the white adipose tissue transcriptome are disturbed in obese individuals with type 2 diabetes compared with lean control individuals.

Authors:  Dirk Jan Stenvers; Aldo Jongejan; Sadaf Atiqi; Jeroen P Vreijling; Eelkje J Limonard; Erik Endert; Frank Baas; Perry D Moerland; Eric Fliers; Andries Kalsbeek; Peter H Bisschop
Journal:  Diabetologia       Date:  2019-02-09       Impact factor: 10.122

5.  Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.

Authors:  Dongyang Liu; Yi Zhang; Ji Jiang; John Choi; Xuening Li; Dalong Zhu; Dawei Xiao; Yanhua Ding; Hongwei Fan; Li Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  NEFA minimal model parameters estimated from the oral glucose tolerance test and the meal tolerance test.

Authors:  Ray C Boston; Peter J Moate
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-18       Impact factor: 3.619

Review 7.  Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

Authors:  Toshikazu Yamanouchi
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 8.  Metabolism as an integral cog in the mammalian circadian clockwork.

Authors:  Karen L Gamble; Martin E Young
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-04-17       Impact factor: 8.250

9.  Improvement of glucose metabolism in patients with impaired glucose tolerance or diabetes by long-term administration of a palatinose-based liquid formula as a part of breakfast.

Authors:  Masae Sakuma; Hidekazu Arai; Akira Mizuno; Makiko Fukaya; Motoi Matsuura; Hajime Sasaki; Hisami Yamanaka-Okumura; Hironori Yamamoto; Yutaka Taketani; Toshio Doi; Eiji Takeda
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

Review 10.  Target for glycemic control: concentrating on glucose.

Authors:  Louis Monnier; Claude Colette
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.